pharmaceutical industry

Brand-name drug prices in the U.S. — more than three times the price in other developed countries — are related neither to the amount of research and development nor their therapeutic value, research shows.

Supreme Court's decision to review the controversial bankruptcy deal involving the maker of Oxycontin means the settlement will remain on hold at least through December.

Industry analysts are skeptical that Federal Trade Commission Chair Lina Khan can win her first fight against a drug industry merger. It will be reviewed by a judge appointed by President Donald Trump.

The Danish drugmaker's move follows a similar announcement by rival Eli Lilly earlier this month. More than 8 million Americans use insulin, according to the American Diabetes Association.

Hillsborough County Circuit Judge Ronald Ficarrotta was appointed to preside over the panel, which will convene for a year. Grand jury members will be drawn from five judicial circuits.

While supporters cheer the PASTEUR Act as an essential strategy to stem the rise of antibiotic-resistant pathogens, critics call it a multibillion-dollar giveaway to Big Pharma.

Increasingly, the FDA is asking drugmakers to remove unproven uses from older drugs that haven't delivered on early results. And drugmakers seeking accelerated approvals are facing tougher hurdles.

Makers of products like Children's Tylenol say they're trying to keep up with big demand as RSV, flu and COVID spread. But medical experts note that kids' fevers don't always call for medicine.

The Biden administration denies the state's allegations that it is "protecting the interests of pharmaceutical companies" or that it has not properly complied with a public records request.

Since pharmaceutical companies started funding their FDA drug applications 30 years ago, the agency’s reviews have gone much faster — perhaps too fast.